How should I prescribe as‑needed metoprolol for an adult with performance‑related anxiety who has no contraindications such as severe bradycardia, high‑grade atrioventricular block, decompensated heart failure, uncontrolled hypotension, or active bronchospasm, and may have mild chronic obstructive pulmonary disease?

Metoprolol for Performance-Related Anxiety: Prescribing Protocol

For performance-related anxiety in adults without cardiac contraindications, prescribe metoprolol tartrate 25–50 mg orally as a single dose 30–60 minutes before the anticipated performance event. 1

Patient Selection and Screening

Before prescribing metoprolol for performance anxiety, verify the absence of absolute contraindications:

• No second- or third-degree AV block (PR interval must be ≤0.24 seconds) 2
• No decompensated heart failure or signs of low cardiac output 2, 1
• No active asthma or severe reactive airway disease 2, 1
• No cardiogenic shock 1
• No severe bradycardia (resting heart rate should be >60 bpm) 2, 1
• No severe hypotension (systolic BP should be >100 mmHg) 1

Special Consideration for Mild COPD

Patients with mild chronic obstructive pulmonary disease can generally tolerate cardioselective beta-blockers like metoprolol. 3 The selective β1-blocker treatment is considered safe for patients with cardiovascular diseases and COPD, and metoprolol can be used in this patient cohort. 3 However, start with the lowest effective dose (12.5–25 mg) and monitor for new or worsening dyspnea, cough, or wheezing. 3, 4

Dosing Protocol

Initial As-Needed Dosing

Start with metoprolol tartrate 25 mg orally as a single dose 30–60 minutes before the performance event. 1 This allows adequate time for peak plasma concentration and maximal beta-blockade effect.

• If 25 mg provides insufficient symptom control (persistent tachycardia, tremor, or anxiety symptoms during performance), increase to 50 mg for subsequent events 1
• Maximum single dose: 50 mg for performance anxiety 1
• Do not exceed one dose per performance event 1

Tablet Splitting for Dose Adjustment

Metoprolol tartrate immediate-release tablets can be split to achieve doses of 12.5 mg if needed for patients who experience excessive bradycardia or hypotension with 25 mg. 5 This is particularly useful when initiating therapy in patients with borderline blood pressure or heart rate. 5

Pre-Dose Monitoring

Before each dose, patients should check:

• Heart rate >60 bpm (hold dose if <60 bpm or symptomatic bradycardia) 1
• Systolic blood pressure >100 mmHg (hold dose if <100 mmHg with symptoms) 1

Patient Education and Safety Instructions

Expected Effects

• Reduced heart rate by 10–20 bpm 1
• Decreased tremor and physical manifestations of anxiety 1
• Onset within 30–60 minutes, lasting 3–4 hours 1

Warning Signs to Hold Dose

Instruct patients to skip the dose and seek medical attention if they experience:

• Dizziness, lightheadedness, or near-syncope 1
• Severe fatigue or weakness 1
• New or worsening shortness of breath (especially in patients with mild COPD) 3, 4
• Wheezing or chest tightness 3, 4

Drug Interactions

Avoid concurrent use with other rate-lowering agents such as:

• Calcium channel blockers (diltiazem, verapamil) 2
• Digoxin 2
• Amiodarone 2

These combinations can cause additive bradycardia and AV block. 2

Common Pitfalls to Avoid

Do Not Use Daily Dosing for Performance Anxiety

Metoprolol for performance anxiety should be prescribed as-needed only, not as daily maintenance therapy. 1 Daily beta-blocker therapy is indicated for hypertension, heart failure, or post-MI secondary prevention—not for situational anxiety. 6, 1

Do Not Prescribe Extended-Release Formulation

Use metoprolol tartrate (immediate-release), not metoprolol succinate (extended-release). 1, 5 The immediate-release formulation allows for predictable onset and offset for single-event dosing, whereas extended-release is designed for once-daily chronic therapy. 1, 5

Do Not Abruptly Discontinue in Patients Who Transition to Daily Use

If a patient later requires daily beta-blocker therapy for a cardiac indication, never abruptly stop metoprolol—this can cause severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias with a 50% mortality rate in one study. 1 Taper by reducing the dose by 25–50% every 1–2 weeks. 1

Follow-Up and Reassessment

• Reassess after 2–3 performance events to determine if the dose is effective and well-tolerated 1
• Monitor for development of tolerance (rare with as-needed use) 1
• Screen for escalating use patterns that might indicate need for alternative anxiety management strategies 1